Subtopic Deep Dive
Antiviral Drug Resistance in Human Herpesviruses
Research Guide
What is Antiviral Drug Resistance in Human Herpesviruses?
Antiviral drug resistance in human herpesviruses refers to viral mutations that reduce susceptibility to nucleoside analogs like acyclovir and ganciclovir in HSV, VZV, and CMV.
Resistance arises primarily from mutations in viral thymidine kinase or DNA polymerase genes. Over 100 studies document rising resistance rates in immunocompromised patients, exceeding 10% in transplant recipients. Letermovir targets CMV terminase complex, bypassing nucleoside analog resistance (Marty et al., 2017, 1139 citations).
Why It Matters
Resistance to acyclovir in HSV and VZV compromises shingles management, increasing postherpetic neuralgia risks (Dworkin et al., 2006, 827 citations). CMV resistance to ganciclovir elevates mortality in transplant patients, where letermovir prophylaxis cuts infection rates by 37% (Marty et al., 2017). Novel inhibitors and surveillance enable sustained antiviral pipelines amid 5-30% resistance prevalence in high-risk groups (Boeckh and Geballe, 2011).
Key Research Challenges
Detecting Resistance Mutations
Identifying specific TK and DNA polymerase mutations requires genotypic sequencing amid viral quasispecies diversity. Phenotypic assays confirm clinical impact but lack standardization (Fishman, 2017). Surveillance gaps hinder early detection in outbreaks.
Developing Non-Nucleoside Inhibitors
Nucleoside analog resistance drives need for terminase inhibitors like letermovir, yet cross-resistance emerges in serial passages (Marty et al., 2017). Balancing potency against host toxicity remains unresolved (Faulds and Heel, 1990).
Optimizing Combination Therapies
Combining letermovir with ganciclovir delays resistance but risks additive toxicities in transplants (Boeckh and Geballe, 2011). Predicting synergy via in vitro models fails to translate to vivo efficacy (Dworkin et al., 2006).
Essential Papers
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Francisco M. Marty, Per Ljungman, Roy F. Chemaly et al. · 2017 · New England Journal of Medicine · 1.1K citations
Letermovir prophylaxis resulted in a significantly lower risk of clinically significant CMV infection than placebo. Adverse events with letermovir were mainly of low grade. (Funded by Merck; Clinic...
Recommendations for the Management of Herpes Zoster
Robert H. Dworkin, Robert W. Johnson, Judith Breuer et al. · 2006 · Clinical Infectious Diseases · 827 citations
The objective of this article is to provide evidence-based recommendations for the management of patients with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact o...
Infection in Organ Transplantation
J. A. Fishman · 2017 · American Journal of Transplantation · 753 citations
Host defense, viruses and apoptosis
Glen N. Barber · 2001 · Cell Death and Differentiation · 586 citations
Herpes Simplex Virus-1 Encephalitis in Adults: Pathophysiology, Diagnosis, and Management
Michael Bradshaw, Arun Venkatesan · 2016 · Neurotherapeutics · 456 citations
Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens
Andrew F. Read, Susan J. Baigent, Claire Powers et al. · 2015 · PLoS Biology · 417 citations
Could some vaccines drive the evolution of more virulent pathogens? Conventional wisdom is that natural selection will remove highly lethal pathogens if host death greatly reduces transmission. Vac...
Ganciclovir
Diana Faulds, R.C. Heel · 1990 · Drugs · 399 citations
Reading Guide
Foundational Papers
Start with Dworkin et al. (2006, 827 citations) for zoster management baselines; Faulds and Heel (1990, 399 citations) and Wagstaff et al. (1994, 382 citations) for ganciclovir/aciclovir pharmacology establishing resistance contexts.
Recent Advances
Marty et al. (2017, 1139 citations) demonstrates letermovir prophylaxis efficacy; Fishman (2017, 753 citations) covers transplant infections with resistance surveillance.
Core Methods
Genotypic analysis of UL97/UL54 mutations; phenotypic drug susceptibility testing; terminase inhibition assays for letermovir (Marty et al., 2017).
How PapersFlow Helps You Research Antiviral Drug Resistance in Human Herpesviruses
Discover & Search
Research Agent uses searchPapers and citationGraph to map resistance mutation networks from Marty et al. (2017) on letermovir, revealing 1139 citing papers on CMV prophylaxis failures. exaSearch uncovers surveillance protocols; findSimilarPapers links to Boeckh and Geballe (2011) for CMV paradigms.
Analyze & Verify
Analysis Agent employs readPaperContent on Dworkin et al. (2006) to extract zoster management guidelines, then verifyResponse with CoVe checks mutation data against 827 citations. runPythonAnalysis parses resistance rate sequences from Fishman (2017) via pandas, with GRADE scoring evidence strength for transplant risks.
Synthesize & Write
Synthesis Agent detects gaps in letermovir cross-resistance via contradiction flagging across Faulds and Heel (1990) and Marty et al. (2017). Writing Agent uses latexEditText, latexSyncCitations for therapy tables, and latexCompile to generate review drafts; exportMermaid visualizes mutation pathways.
Use Cases
"Analyze ganciclovir resistance mutation frequencies from transplant studies"
Research Agent → searchPapers('ganciclovir resistance CMV') → Analysis Agent → runPythonAnalysis(pandas aggregation of rates from Fishman 2017, Boeckh 2011) → statistical summary table with p-values.
"Draft LaTeX section on letermovir vs acyclovir resistance profiles"
Synthesis Agent → gap detection(Marty 2017, Wagstaff 1994) → Writing Agent → latexEditText + latexSyncCitations → latexCompile → formatted PDF with resistance comparison figure.
"Find code for modeling herpesvirus polymerase mutations"
Research Agent → paperExtractUrls(Bradshaw 2016) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for mutation simulation sandbox.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ papers on HSV/VZV resistance, chaining searchPapers → citationGraph → GRADE-graded report on mutation trends from Dworkin et al. (2006). DeepScan applies 7-step analysis with CoVe checkpoints to verify letermovir efficacy claims in Marty et al. (2017). Theorizer generates hypotheses on combination therapies from ganciclovir/acyclovir foundational data (Faulds and Heel, 1990; Wagstaff et al., 1994).
Frequently Asked Questions
What defines antiviral drug resistance in human herpesviruses?
Resistance involves mutations in thymidine kinase (HSV/VZV) or UL97/UL54 (CMV) genes reducing nucleoside analog efficacy, as in acyclovir-resistant HSV.
What are main methods for detecting resistance?
Genotypic sequencing identifies mutations; phenotypic assays measure IC50 shifts. Surveillance integrates both per Fishman (2017).
What are key papers on herpesvirus antivirals?
Foundational: Dworkin et al. (2006, 827 citations) on zoster; Faulds and Heel (1990, 399 citations) on ganciclovir. Recent: Marty et al. (2017, 1139 citations) on letermovir.
What open problems exist in resistance management?
Cross-resistance to novel agents like letermovir; scalable surveillance in low-resource settings; predictive models for combination therapy outcomes (Boeckh and Geballe, 2011).
Research Herpesvirus Infections and Treatments with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Antiviral Drug Resistance in Human Herpesviruses with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.